ImmuPharma (LON:IMM) Shares Up 39.7% – Here’s Why

Shares of ImmuPharma plc (LON:IMM) shot up 39.7% during mid-day trading on Monday . The company traded as high as GBX 7.20 ($0.10) and last traded at GBX 7.20 ($0.10). 16,765,875 shares were traded during mid-day trading, an increase of 134% from the average session volume of 7,166,685 shares. The stock had previously closed at GBX 5.16 ($0.07).

ImmuPharma Stock Performance

The company has a market cap of £63.14 million, a PE ratio of -1,419.55 and a beta of 1.53. The stock has a 50 day moving average of GBX 2.55 and a 200-day moving average of GBX 2.76.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.